证券代码：002317 公告编号：2025-119 广东众生药业股份有限公司 2025 年第四次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次临时股东大会以现场投票和网络投票相结合的方式召开。 2、本次临时股东大会不存在否决提案，无涉及变更前次股东大会决议的情 形。 一、会议召开和出席情况 广东众生药业股份有限公司（以下简称"公司"）2025 年第四次临时股东大 会采取现场投票与网络投票相结合的方式召开。 （一）会议召开的时间： 1、现场会议召开时间：2025 年 12 月 29 日下午 2:45 2、网络投票时间： （1）通过深交所交易系统进行网络投票的具体时间为 2025 年 12 月 29 日 9:15～9:25，9:30～11:30 和 13:00～15:00； （四）现场会议主持人：公司董事长陈永红先生。 （2）通过互联网投票系统投票的具体时间为2025年12月29日9:15～15:00。 （二）现场会议召开地点：公司会议室 （五）会议出席情况： 出席本次会议的股东及股东代理人 611 人，代表股份 239 ...

证券代码：002317 公告编号：2025-121 广东众生药业股份有限公司 第九届董事会第一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 12 月 29 日召 开 2025 年第四次临时股东大会、职工代表大会，换届选举产生了公司第九届董 事会成员，为保证董事会工作的连贯性，第九届董事会第一次会议的会议通知于 2025 年 12 月 24 日以专人和电子邮件预通知方式送达全体董事，会议于 2025 年 12 月 29 日在公司会议室以现场和通讯表决方式召开。本次会议应出席董事 9 人， 实际出席董事 9 人。经全体董事一致推举，会议由陈永红先生主持，董事会秘书 列席会议。本次会议的召集和召开符合法律、法规和《公司章程》的有关规定。 经与会董事认真审议，以记名投票方式表决，做出如下决议： 一、审议通过了《关于选举公司第九届董事会董事长的议案》。 公司第九届董事会成员已经公司 2025 年第四次临时股东大会及职工代表大 会选举产生。本次会议选举陈永红先生担任公司第九届董事会董事长，任期 ...

众生药业公告称，公司于2025年12月29日召开第九届董事会第一次会议。会议选举陈永红为董事长，张 玉冲为副董事长，还选举了各专门委员会成员。此外，聘任陈永红为总裁，张玉冲为高级副总裁，龙春 华、刘霜、罗日康、陈小新为副总裁；聘任杨威为董事会秘书，龙春华兼任财务总监，以上人员任期均 与本届董事会一致。罗日康直接持有公司0.0012%股份，其他新聘人员未直接持股。 ...

北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第四次临时股东大会的法律意见书 中国·北京 北京市朝阳区建外大街甲 14 号广播大厦 5 层&9 层&10 层&13 层&17 层 电话（Tel）：86-10-65219696 传真（Fax）：86-10-88381869 北京海润天睿律师事务所 关于广东众生药业股份有限公司 2025 年第四次临时股东大会的法律意见书 致：广东众生药业股份有限公司 北京海润天睿律师事务所（以下简称"本所"）接受广东众生药业股份有限 公司（以下简称"公司"）的委托，指派张圣怀律师、冯玫律师出席公司 2025 年第四次临时股东大会，并依据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《广东众 生药业股份有限公司章程》（以下简称"《公司章程》")及其他相关法律、法 规和规范性文件的规定，就公司本次股东大会的召集、召开程序、出席会议人员 的资格、召集人资格、表决程序、表决结果等有关事宜出具本法律意见书。 对本法律意见书的出具，本所律师特作如下声明： 1．本所及经办律师依据《证券法》《律师事务所从事证券法律业务 ...

Core Viewpoint - The traditional Chinese medicine sector experienced a slight decline of 0.12% on December 26, with ST Bailin leading the drop, while the overall Shanghai Composite Index rose by 0.1% [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 3963.68, up 0.1% [1]. - The Shenzhen Component Index closed at 13603.89, up 0.54% [1]. - The traditional Chinese medicine sector saw a net outflow of 229 million yuan from major funds, while retail investors contributed a net inflow of 195 million yuan [2][3]. Group 2: Individual Stock Performance - Notable gainers included: - Zhongsheng Pharmaceutical (002317) with a closing price of 20.06, up 2.92% [1]. - Wanbangde (002082) closed at 13.70, up 2.09% [1]. - Tongrentang (600085) closed at 32.25, up 1.26% [1]. - Major decliners included: - ST Bailin (002424) closed at 4.59, down 4.97% [2]. - *ST Changyao (300391) closed at 1.47, down 3.92% [2]. - Jinhua Co. (600080) closed at 7.76, down 2.51% [2]. Group 3: Trading Volume and Capital Flow - Zhongsheng Pharmaceutical had a trading volume of 747,200 shares and a transaction value of 149 million yuan [1]. - ST Bailin had a trading volume of 849,300 shares with a transaction value of 391 million yuan [2]. - The capital flow data indicates that major funds had a net inflow in Zhongsheng Pharmaceutical, while other stocks like Tongrentang and Wanbangde saw mixed capital flows [3].

Group 1: Zhongsheng Pharma - The core business of Zhongsheng Pharma has stabilized after experiencing centralized procurement, with innovative drug research and development gradually yielding results, particularly in respiratory and metabolic fields [2][4] - The company reported a revenue of 1.889 billion yuan for the first three quarters of 2025, a year-on-year decrease of 1.01%, while net profit attributable to shareholders increased by 68.40% to 251 million yuan [4] - The core products of traditional Chinese medicine have maintained stable growth post-collective procurement, with sales resilience supported by volume compensating for price reductions [4][5] - The innovative pipeline includes RAY1225 injection, a dual-target drug for weight loss and blood sugar reduction, which has shown positive results in clinical trials [5] Group 2: Medical Device Industry - The brain-computer interface (BCI) industry in China has achieved rapid development under policy support, with a focus on establishing a robust technological and industrial framework by 2027 [6][8] - The National Medical Products Administration held a meeting to discuss the advancement of BCI medical devices, emphasizing safety and effectiveness as primary considerations [17] - By 2030, the BCI industry aims to cultivate globally influential leading enterprises and a competitive industrial ecosystem, with significant advancements expected in technology and application [18]

Macro Research - The core viewpoint of the report indicates that the US economy showed resilience in Q3 2025, with a GDP growth rate of 4.3%, surpassing expectations of 3.3% and the previous value of 3.8% [3][20] - Key drivers of this resilience include strong personal consumption, increased public spending, and enhanced export contributions, with capital market wealth effects supporting consumer spending [3][20] - The report highlights a "K" shaped economic divergence, characterized by income disparities affecting consumption, varying business conditions between large and small enterprises, and differences in investment growth between new and old economies [4][21] Strategy Research - The report emphasizes that Chinese companies are entering a new phase of globalization, aiming to capture high-value segments of the global value chain [9][25] - It notes that the acceleration of Chinese enterprises going abroad is a strategic response to rising domestic costs and tightening external market access, which is essential for high-quality development [9][25] - The report predicts that the demand for capital goods in China will remain strong, driven by industrialization and infrastructure investment in emerging markets [11][27] Biopharmaceutical Research - The report discusses the release of the sixth batch of medical device procurement documents, indicating a moderate expected price drop and a favorable situation for domestic manufacturers to increase market share [13][29] - It provides specific data on the expected demand for various medical devices, highlighting the market shares of different companies in the procurement process [30][32] - The report maintains a "buy" rating for companies likely to benefit from the procurement, such as Lepu Medical and Mindray Medical [29][30]

Core Viewpoint - The company has received approval for a new product, which is expected to enhance its product line in the respiratory system and complement its existing innovative drugs [2]. Group 1: Company Performance - As of December 24, 2025, the stock price of Zhongsheng Pharmaceutical (002317) closed at 19.46 yuan, down 0.05%, with a turnover rate of 7.28%, trading volume of 554,100 hands, and a transaction amount of 1.08 billion yuan [1]. - On the same day, the net outflow of main funds was 2.8084 million yuan, while the net inflow of speculative funds was 21.1941 million yuan, and the net outflow of retail funds was 18.3858 million yuan [1][3]. Group 2: Product Development - The company has obtained the drug registration certificate for Ambroxol Hydrochloride Oral Solution, with approved specifications of 10ml:30mg and 100ml:0.3g, classified as a Category 4 chemical drug, equivalent to passing the consistency evaluation for generic drugs [2]. - The Ambroxol Hydrochloride Oral Solution is indicated for the treatment of viscous phlegm and difficulty in expectoration caused by acute and chronic bronchitis, and it is listed as a Class B drug under medical insurance [2]. - The projected sales for this product in Chinese public hospitals and urban retail pharmacies are 710.84 million yuan for 2022, 817.66 million yuan for 2023, and 849.53 million yuan for 2024 [2].

本报讯 （记者李雯珊见习记者张美娜）12月23日，广东众生药业股份有限公司（以下简称"公司"）发 布公告，公司近日收到国家药监局核准签发的盐酸氨溴索口服溶液《药品注册证书》。根据公告，盐酸 氨溴索口服溶液适用于急、慢性支气管炎引起的痰液黏稠、咳痰困难，有明确的诊疗指南推荐。 （文章来源：证券日报） ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002317 公告编号：2025-118 广东众生药业股份有限公司关于获得盐酸氨溴索口服溶液《药品注册证书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 广东众生药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局核准签发的盐酸氨溴索 口服溶液《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要信息 药品名称：盐酸氨溴索口服溶液 剂型：口服溶液剂 规格：10ml∶30mg、100ml∶0.3g 申请事项：药品注册（境内生产） 注册分类：化学药品4类 证书编号：2025S03794、2025S03795 药品批准文号：国药准字H20256278、国药准字H20256279 上市许可持有人：名称：广东众生药业股份有限公司，地址：广东省东莞市石龙镇西湖工业区信息产业 园 生产企业：名称：广东众生药业股份有限公司，地址：广东省东莞市石龙镇西湖工业区信息产业园 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。 ...